239 related articles for article (PubMed ID: 35628540)
1. Checkpoint kinase 1 inhibitor + low-dose hydroxyurea efficiently kills BRAF inhibitor- and immune checkpoint inhibitor-resistant melanomas.
Zeng Z; Ngo HL; Proctor M; Rizos H; Dolcetti R; Cruz JG; Wells JW; Gabrielli B
Pigment Cell Melanoma Res; 2024 Jan; 37(1):45-50. PubMed ID: 37614154
[TBL] [Abstract][Full Text] [Related]
2. Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy.
Wang Y; Liu S; Yang Z; Algazi AP; Lomeli SH; Wang Y; Othus M; Hong A; Wang X; Randolph CE; Jones AM; Bosenberg MW; Byrum SD; Tackett AJ; Lopez H; Yates C; Solit DB; Ribas A; Piva M; Moriceau G; Lo RS
Cancer Cell; 2021 Oct; 39(10):1375-1387.e6. PubMed ID: 34416167
[TBL] [Abstract][Full Text] [Related]
3. Updates in Therapy for Advanced Melanoma.
Singh BP; Salama AK
Cancers (Basel); 2016 Jan; 8(1):. PubMed ID: 26784231
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial Therapies in Thyroid Cancer: An Overview of Preclinical and Clinical Progresses.
Laetitia G; Sven S; Fabrice J
Cells; 2020 Mar; 9(4):. PubMed ID: 32235612
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in anaplastic thyroid cancer management.
Hamidi S; Maniakas A
Curr Opin Endocrinol Diabetes Obes; 2023 Oct; 30(5):259-264. PubMed ID: 37410453
[TBL] [Abstract][Full Text] [Related]
6. Anti-Proliferative Effect of Radiotherapy and Implication of Immunotherapy in Anaplastic Thyroid Cancer Cells.
Wächter S; Roth S; Gercke N; Schötz U; Dikomey E; Engenhart-Cabillic R; Maurer E; Bartsch DK; Di Fazio P
Life (Basel); 2023 Jun; 13(6):. PubMed ID: 37374179
[TBL] [Abstract][Full Text] [Related]
7. Challenges and Strategies to Combat Resistance Mechanisms in Thyroid Cancer Therapeutics.
Gild ML; Bullock M; Tsang V; Clifton-Bligh RJ; Robinson BG; Wirth LJ
Thyroid; 2023 Jun; 33(6):682-690. PubMed ID: 36924302
[No Abstract] [Full Text] [Related]
8. Molecular features of aggressive thyroid cancer.
Elia G; Patrizio A; Ragusa F; Paparo SR; Mazzi V; Balestri E; Botrini C; Rugani L; Benvenga S; Materazzi G; Spinelli C; Antonelli A; Fallahi P; Ferrari SM
Front Oncol; 2022; 12():1099280. PubMed ID: 36605433
[TBL] [Abstract][Full Text] [Related]
9. Exploring the clinical utility of angioinvasion markers in papillary thyroid cancer: a literature review.
Buczyńska A; Kościuszko M; Krętowski AJ; Popławska-Kita A
Front Endocrinol (Lausanne); 2023; 14():1261860. PubMed ID: 38089632
[TBL] [Abstract][Full Text] [Related]
10. Knowledge mapping of immunotherapy for thyroid cancer from 1980 to 2022: A review.
Ding R; Jiao H; Piao Y; Tian W
Medicine (Baltimore); 2023 Sep; 102(39):e35506. PubMed ID: 37773801
[TBL] [Abstract][Full Text] [Related]
11. A Theranostic Approach to Imaging and Treating Melanoma with
Jiao R; Allen KJH; Malo ME; Yilmaz O; Wilson J; Nelson BJB; Wuest F; Dadachova E
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568672
[TBL] [Abstract][Full Text] [Related]
12. Insights on the Association between Thyroid Diseases and Colorectal Cancer.
Gagliardi F; Baldini E; Lori E; Cardarelli S; Pironi D; Lauro A; Tripodi D; Palumbo P; D'Armiento E; Cavallaro G; Polistena A; D'Orazi V; Sibio S; Fallahi P; Antonelli A; D'Andrea V; Ulisse S; Sorrenti S
J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983233
[TBL] [Abstract][Full Text] [Related]
13. Editorial: Differential diagnoses of thyroid neoplasms: Molecular and histological features and the impact on follow-up.
Sorrenti S; Lauro A; Pironi D; Calò PG; Ulisse S
Front Oncol; 2023; 13():1125887. PubMed ID: 36798815
[No Abstract] [Full Text] [Related]
14. Tackling Thyroid Cancer in Europe-The Challenges and Opportunities.
Horgan D; Führer-Sakel D; Soares P; Alvarez CV; Fugazzola L; Netea-Maier RT; Jarzab B; Kozaric M; Bartes B; Schuster-Bruce J; Dal Maso L; Schlumberger M; Pacini F
Healthcare (Basel); 2022 Aug; 10(9):. PubMed ID: 36141235
[TBL] [Abstract][Full Text] [Related]
15. Is Melanoma Progression Affected by Thyroid Diseases?
Ulisse S; Baldini E; Pironi D; Gagliardi F; Tripodi D; Lauro A; Carbotta S; Tarroni D; D'Armiento M; Morrone A; Forte F; Frattaroli F; Persechino S; Odorisio T; D'Andrea V; Lori E; Sorrenti S
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077430
[TBL] [Abstract][Full Text] [Related]
16. Targeting Melanin in Melanoma with Radionuclide Therapy.
Allen KJH; Malo ME; Jiao R; Dadachova E
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076924
[TBL] [Abstract][Full Text] [Related]
17. Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer.
Ragusa F; Ferrari SM; Elia G; Paparo SR; Balestri E; Botrini C; Patrizio A; Mazzi V; Guglielmi G; Foddis R; Spinelli C; Ulisse S; Antonelli A; Fallahi P
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628540
[TBL] [Abstract][Full Text] [Related]
18. Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade.
Shin MH; Kim J; Lim SA; Kim J; Lee KM
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260561
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
